NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.

Liver fibrosis is a worldwide clinical issue. It has been well established that activated hepatic stellate cells (HSCs) are responsible for excessive extracellular matrix (ECM) deposition in chronically damaged livers. The identification of key elements that control HSCs activation will help to furt...

Full description

Bibliographic Details
Main Authors: Jiandong Yang, Jin Zheng, Lin Wu, Ming Shi, Hongtao Zhang, Xing Wang, Ning Xia, Desheng Wang, Xinping Liu, Libo Yao, Yan Li, Kefeng Dou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22110735/pdf/?tool=EBI
_version_ 1818735782648610816
author Jiandong Yang
Jin Zheng
Lin Wu
Ming Shi
Hongtao Zhang
Xing Wang
Ning Xia
Desheng Wang
Xinping Liu
Libo Yao
Yan Li
Kefeng Dou
author_facet Jiandong Yang
Jin Zheng
Lin Wu
Ming Shi
Hongtao Zhang
Xing Wang
Ning Xia
Desheng Wang
Xinping Liu
Libo Yao
Yan Li
Kefeng Dou
author_sort Jiandong Yang
collection DOAJ
description Liver fibrosis is a worldwide clinical issue. It has been well established that activated hepatic stellate cells (HSCs) are responsible for excessive extracellular matrix (ECM) deposition in chronically damaged livers. The identification of key elements that control HSCs activation will help to further our understanding of liver fibrosis and improve the outcome of clinical treatment. This study demonstrates that N-Myc downstream-regulated gene 2 (NDRG2) is a potential regulator of liver fibrosis as NDRG2 mRNA and protein levels were reduced during HSCs activation. In addition, enhanced NDRG2 expression reduced Smad3 transcription and phosphorylation, which inhibited HSCs activation by blocking the TGF-β1 signal. Moreover, NDRG2 contributed to an increase in the ratio of matrix metalloproteinase 2 (MMP2) to tissue inhibitor of matrix metalloproteinase 2 (TIMP2), which may facilitate the degradation of the ECM. In dimethylnitrosamine (DMN)-induced fibrotic rat livers, adenovirus-mediated NDRG2 overexpression resulted in decreased ECM deposition and improved liver function compared with controls. In conclusion, the present findings indicate that the modulation of NDRG2 is a promising strategy for the treatment of liver fibrosis.
first_indexed 2024-12-18T00:26:44Z
format Article
id doaj.art-e1c3f31c3d8d4426b6c447a7cdb7943a
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-18T00:26:44Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-e1c3f31c3d8d4426b6c447a7cdb7943a2022-12-21T21:27:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01611e2771010.1371/journal.pone.0027710NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.Jiandong YangJin ZhengLin WuMing ShiHongtao ZhangXing WangNing XiaDesheng WangXinping LiuLibo YaoYan LiKefeng DouLiver fibrosis is a worldwide clinical issue. It has been well established that activated hepatic stellate cells (HSCs) are responsible for excessive extracellular matrix (ECM) deposition in chronically damaged livers. The identification of key elements that control HSCs activation will help to further our understanding of liver fibrosis and improve the outcome of clinical treatment. This study demonstrates that N-Myc downstream-regulated gene 2 (NDRG2) is a potential regulator of liver fibrosis as NDRG2 mRNA and protein levels were reduced during HSCs activation. In addition, enhanced NDRG2 expression reduced Smad3 transcription and phosphorylation, which inhibited HSCs activation by blocking the TGF-β1 signal. Moreover, NDRG2 contributed to an increase in the ratio of matrix metalloproteinase 2 (MMP2) to tissue inhibitor of matrix metalloproteinase 2 (TIMP2), which may facilitate the degradation of the ECM. In dimethylnitrosamine (DMN)-induced fibrotic rat livers, adenovirus-mediated NDRG2 overexpression resulted in decreased ECM deposition and improved liver function compared with controls. In conclusion, the present findings indicate that the modulation of NDRG2 is a promising strategy for the treatment of liver fibrosis.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22110735/pdf/?tool=EBI
spellingShingle Jiandong Yang
Jin Zheng
Lin Wu
Ming Shi
Hongtao Zhang
Xing Wang
Ning Xia
Desheng Wang
Xinping Liu
Libo Yao
Yan Li
Kefeng Dou
NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
PLoS ONE
title NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
title_full NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
title_fullStr NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
title_full_unstemmed NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
title_short NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.
title_sort ndrg2 ameliorates hepatic fibrosis by inhibiting the tgf β1 smad pathway and altering the mmp2 timp2 ratio in rats
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22110735/pdf/?tool=EBI
work_keys_str_mv AT jiandongyang ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT jinzheng ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT linwu ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT mingshi ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT hongtaozhang ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT xingwang ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT ningxia ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT deshengwang ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT xinpingliu ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT liboyao ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT yanli ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats
AT kefengdou ndrg2ameliorateshepaticfibrosisbyinhibitingthetgfb1smadpathwayandalteringthemmp2timp2ratioinrats